The effect of targeting CD73 is likely to be mediated by eradicating the immunosuppressive and proangiogenic niche within the TME that is regulated by CD73, as stimulating the immune response can facilitate the elimination of the residual cancer cells. The gene discussed is NT5E; the disease is cancer.